Q: What is Helicobacter pylori and how does it cause disease?

Helicobacter pylori (H. pylori) is a gram-negative, helical-shaped bacterium that colonizes the human gastric mucosa. It is one of the most common chronic bacterial infections in humans, affecting approximately 44% of the global population. The bacterium survives in the harsh acidic environment of the stomach by producing urease, an enzyme that converts urea to ammonia and carbon dioxide, creating a protective neutral microenvironment around the bacteria. The pathogenic mechanisms of H. pylori are multifaceted. The bacterium produces several virulence factors, including cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), which damage gastric epithelial cells, disrupt tight junctions, and trigger inflammatory responses. Chronic inflammation leads to gastric mucosal injury, which can progress through a cascade from gastritis to gastric atrophy, intestinal metaplasia, and in some cases gastric cancer. H. pylori is the primary cause of peptic ulcer disease, responsible for approximately 70% of gastric ulcers and 90% of duodenal ulcers. It is also classified as a Group I carcinogen by the International Agency for Research on Cancer (IARC), with chronic infection significantly increasing the risk of both gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

Question 1

What is Helicobacter pylori and how does it cause disease?

Accepted Answer

Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects the gastric mucosa of approximately 44% of the world’s population. As a World Health Organization Group I carcinogen and the primary cause of peptic ulcer disease, H. pylori represents one of the most significant infectious causes of human morbidity and mortality worldwide.

The Scriabin Research Program at AstraZeneca R&D Boston is dedicated to advancing understanding of H. pylori pathogenesis, improving eradication strategies, and developing the next generation of therapeutic interventions for H. pylori-associated diseases.

The pathogenic mechanisms of H. pylori are multifaceted. The bacterium produces several virulence factors, including cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), which damage gastric epithelial cells, disrupt tight junctions, and trigger inflammatory responses. Chronic inflammation leads to gastric mucosal injury, which can progress through a cascade from gastritis to gastric atrophy, intestinal metaplasia, and in some cases gastric cancer.

H. pylori is the primary cause of peptic ulcer disease, responsible for approximately 70% of gastric ulcers and 90% of duodenal ulcers. It is also classified as a Group I carcinogen by the International Agency for Research on Cancer (IARC), with chronic infection significantly increasing the risk of both gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

Question 2

How is H. pylori diagnosed?

Accepted Answer

H. pylori can be diagnosed using non-invasive and invasive methods, each with different sensitivity, specificity, and clinical applications. Non-invasive tests include the urea breath test (UBT), which detects urease activity by having the patient ingest labeled urea and measuring labeled CO₂ in the breath — the gold standard non-invasive test with sensitivity and specificity exceeding 95%. Stool antigen testing offers similar accuracy and is particularly useful for confirming eradication after treatment.

Serological testing (blood antibody tests) can detect H. pylori antibodies but cannot distinguish between active and past infection, making it unsuitable for post-treatment confirmation. It is still useful for epidemiological studies and initial screening in some settings.

Invasive methods require upper endoscopy (gastroscopy) to obtain biopsy specimens from the gastric mucosa. Rapid urease tests (RUT) provide results within hours; histological examination with appropriate staining allows direct visualization of the bacteria; and culture permits antibiotic susceptibility testing to guide treatment selection in cases of treatment failure.

Question 3

What are the current standard treatments for H. pylori?

Accepted Answer

First-line treatment for H. pylori typically involves combination antibiotic therapy paired with proton pump inhibitor (PPI) therapy to reduce gastric acidity and enhance antibiotic efficacy. Standard triple therapy — a PPI plus clarithromycin and amoxicillin (or metronidazole) for 7–14 days — was historically the most widely used regimen, achieving eradication rates of 70–85% in regions with low clarithromycin resistance.

Rising antibiotic resistance, particularly to clarithromycin and metronidazole, has prompted the adoption of more potent regimens in many regions. Bismuth-containing quadruple therapy (bismuth subcitrate, tetracycline, metronidazole, and a PPI) achieves eradication rates of 85–95% and remains effective even in areas with high clarithromycin resistance. Concomitant therapy (PPI + clarithromycin + amoxicillin + metronidazole simultaneously for 10–14 days) has also demonstrated high efficacy in resistant settings.

Potassium-competitive acid blockers (P-CABs), a newer class of gastric acid suppressants, are increasingly being incorporated into H. pylori eradication regimens due to their more consistent and potent acid suppression compared to conventional PPIs. AstraZeneca has a long history with PPI-based therapies relevant to H. pylori eradication, including significant contributions to the understanding of acid suppression pharmacology.

Question 4

What are the public health implications of H. pylori?

Accepted Answer

H. pylori infection represents a significant global public health challenge. With approximately 44% of the world’s population infected, the bacterium causes substantial morbidity through peptic ulcer disease and is estimated to be responsible for approximately 780,000 deaths annually from gastric cancer worldwide — making it one of the most consequential human pathogens from a population health perspective.

The infection disproportionately affects populations in developing countries, where prevalence rates can exceed 70–90%, compared to 25–50% in developed nations. Transmission occurs primarily through the fecal-oral route or oral-oral contact, often in early childhood, with overcrowding, poor sanitation, and inadequate access to clean water being key risk factors for high transmission rates in resource-limited settings.

Population-level screening and eradication programs have been implemented in several countries, particularly in East Asia where gastric cancer incidence is highest. Evidence suggests that eradicating H. pylori at a population level can significantly reduce gastric cancer incidence. The World Health Organization has increasingly recognized H. pylori as a priority pathogen for elimination strategies, driving research investment in vaccines and improved diagnostic and therapeutic approaches.

Question 5

What is AstraZeneca's role in H. pylori research?

Accepted Answer

AstraZeneca has a deep and historically significant role in the field of H. pylori-related research, stemming from the company’s leadership in proton pump inhibitor (PPI) development. Omeprazole (Prilosec), developed by Astra AB (which later became AstraZeneca through the merger with Zeneca), was the world’s first PPI and transformed the treatment of acid-related gastrointestinal disorders, including those associated with H. pylori. Esomeprazole (Nexium), the S-isomer of omeprazole, represented the next generation of this therapeutic approach.

PPIs are a cornerstone component of H. pylori eradication regimens because they raise gastric pH, which enhances the stability and antimicrobial efficacy of the antibiotics used in combination therapy. AstraZeneca’s pharmacological expertise in acid suppression has contributed substantially to optimizing eradication protocols and understanding the pharmacokinetic factors that influence treatment success.

The Scriabin Research Initiative at AstraZeneca R&D Boston continues this legacy by advancing research into the host-pathogen interactions that determine infection outcomes, novel therapeutic targets for H. pylori eradication, and the longer-term gastrointestinal consequences of infection and its treatment. The program’s collaborative approach integrates basic science with translational medicine to accelerate the path from discovery to clinical application.

Helicobacter Pylori Research

Program Resources

H. Pylori Information

Press Releases

Scientific Publications

Key Facts About H. Pylori

Research Overview

Frequently Asked Questions